Azithromycin pharmacokinetics and molecular data

List of drug pharmacokinetics
Metabolism Elimination Hepatic Insufficiency Gender Geriatric Patients

Metabolism
In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed. Return to top

Elimination
Serum azithromycin concentrations following a single 2.0 g dose of Zmax declined in a polyphasic pattern with a terminal elimination half-life of 59 hours. The prolonged terminal half-life is thought to be due to a large apparent volume of distribution. Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine. Return to top

Hepatic Insufficiency
The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established. Return to top

Gender
The impact of gender on the pharmacokinetics of azithromycin has not been evaluated for Zmax. However, previous studies have demonstrated no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment of Zmax is recommended based on gender. Return to top

Geriatric Patients
The pharmacokinetics of azithromycin following administration of Zmax has not been evaluated in geriatric patients. Pediatric Patients Zmax is not approved for pediatric patients. Return to top